Starpharma Holdings Ltd (ASX:SPL) Stock Price, Trades & News

Starpharma Holdings Ltd is an Australian biotechnology company focused on developing targeted oncology therapeutics, including radiopharmaceuticals, using its clinically validated DEP (Dendrimer Enhanced Product) drug delivery platform. Leveraging more than 20 years of dendrimer expertise, it is advancing novel, proprietary assets and strategic partnerships aimed at improving patient outcomes.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	15.58
Equity-to-Asset	0.72
Debt-to-Equity	0.05
Debt-to-EBITDA	-0.09
Interest Coverage	No Debt
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	19.5	Distress Grey Safe
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	58.7
	3-Year EBITDA Growth Rate	22.6
	3-Year EPS without NRI Growth Rate	24.2
	3-Year FCF Growth Rate	38.3
	3-Year Book Growth Rate	-27.2
	Future 3-5Y Total Revenue Growth Rate Estimate	64.89

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	69.35
	9-Day RSI	62.93
	14-Day RSI	60.07
	3-1 Month Momentum %	4.85
	6-1 Month Momentum %	59.55
	12-1 Month Momentum %	487.14

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.4
	Quick Ratio	3.08
	Cash Ratio	2.13
	Days Inventory	880.74
	Days Sales Outstanding	119.78
	Days Payable	1120.64

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.8
	Shareholder Yield %	0.51

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	93.82
	Operating Margin %	-74.64
	Net Margin %	-61.95
	EBITDA Margin %	-67.08
	FCF Margin %	-29.02
	OCF Margin %	-26.64
	ROE %	-41.28
	ROA %	-31.72
	ROIC %	-155.92
	3-Year ROIIC %	-133.34
	ROC (Joel Greenblatt) %	-212.31
	ROCE %	-48.53
	Years of Profitability over Past 10-Year	1
	Moat Score	4
	Tariff Resilience Score	6

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	385
	PS Ratio	30.77
	PB Ratio	25
	Price-to-Tangible-Book	26.67
	EV-to-EBIT	-39.71
	EV-to-EBITDA	-44.18
	EV-to-Revenue	29.64
	EV-to-Forward-Revenue	9.88
	EV-to-FCF	-93.23
	Price-to-GF-Value	1.74
	Price-to-Median-PS-Value	0.39
	Price-to-Net-Current-Asset-Value	26.67
	Price-to-Net-Cash	80
	Earnings Yield (Greenblatt) %	-2.53
	FCF Yield %	-0.95

Financials

Annual Semi-Annual TTM

ASX:SPL's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Semi-Annual

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Starpharma Holdings Ltd Executives

Details

GF Value™: A$0.46

ASX:SPL

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Good signs with SPL. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil A$)	12.05
	EPS (TTM) (A$)	-0.017
	Beta	0.5967
	3-Year Sharpe Ratio	0.93
	3-Year Sortino Ratio	2.99
	Volatility %	112.78
	14-Day RSI	60.07
	14-Day ATR (A$)	0.03528
	20-Day SMA (A$)	0.749
	12-1 Month Momentum %	487.14
	52-Week Range (A$)	0.116905 - 0.83
	Shares Outstanding (Mil)	477.05

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Starpharma Holdings Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Starpharma Holdings Ltd Stock Events

Financials Calendars

	Event	Date	Price (A$)
No Event Data

Starpharma Holdings Ltd Frequently Asked Questions

What is Starpharma Holdings Ltd(ASX:SPL)'s stock price today?

The current price of ASX:SPL is A$0.80. The 52 week high of ASX:SPL is A$0.83 and 52 week low is A$0.12.

When is next earnings date of Starpharma Holdings Ltd(ASX:SPL)?

The next earnings date of Starpharma Holdings Ltd(ASX:SPL) is .

Does Starpharma Holdings Ltd(ASX:SPL) pay dividends? If so, how much?

Starpharma Holdings Ltd(ASX:SPL) does not pay dividend.

Press Release

	Subject	Date
	Starpharma signs new DEP® agreement with MSD	2022-08-10
	Starpharma releases positive DEP® phase 2 interim results in prostate cancer	2021-11-26
	US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments	2021-09-15
	Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model	2021-08-23
	Starpharma signs DEP® ADC Research Agreement with MSD	2021-02-11
	Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2	2020-09-14
	Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2	2020-09-14
	Starpharma creates slow release soluble DEP remdesivir nanoparticle	2020-09-01
	Starpharma SPL7013 Nasal Spray for COVID-19 – Development Update	2020-08-25
	Starpharma's SPL7013 Shows Significant Activity Against SARS-CoV-2 (coronavirus)	2020-04-16

10/Page

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by FactSet. Analyst estimates data is sourced from both Refinitiv and FactSet, with priority given to Refinitiv data. Data is updated daily.